Evidence map›Paper›PMID 42722782›Full record

ArticleBritish journal of cancer2026

Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment.

Jahlisa S Hooiveld-Noeken, Pim P van de Donk, Laura Kist de Ruijter, Iris C Kok, Claudia A J van Winkel, Danique Giesen, Marjolijn N Lub-de Hooge, Adrienne H Brouwers, Sjoukje F Oosting, Frederike Bensch and 10 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02453984 naunknown statusnot on this map

ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors Prior to and During MPDL3280A Treatment

TypeinterventionalSponsorUniversity Medical Center GroningenRan2016 to 2024Enrolled45ConditionsLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionArms89Zr-MPDL-3280A-PET scans
NCT02478099 phase2unknown statusnot on this map

MPDL3280A Treatment in Patients With Locally Advanced or Metastatic Solid Tumors After or During Investigational Imaging

TypeinterventionalSponsorUniversity Medical Center GroningenRan2016 to 2024Enrolled81ConditionsLocally Advanced or Metastatic Solid TumorsArmsMPDL3280A
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jahlisa S Hooiveld-NoekenDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Pim P van de DonkDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Laura Kist de RuijterDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Iris C KokDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Claudia A J van WinkelDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Danique GiesenDepartments of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Marjolijn N Lub-de HoogeDepartments of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Adrienne H BrouwersDepartments of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-2698-1516
Sjoukje F OostingDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-2754-6997
Frederike BenschDepartments of Pulmonary Diseases, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Lotte M SmitDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-6010-8713
Carolien P SchröderDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Mathilde JalvingDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-9142-9050
Sjoerd G EliasDepartment of Epidemiology and Health Economics, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Jourik A GietemaDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-0629-7354
Regula J DeurlooTranslational Medicine Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Simon P WilliamsGenentech, San Francisco, CA, USA.
Alexander UngewickellGenentech, San Francisco, CA, USA.
Derk-Jan A de GrootDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-8306-6835
Elisabeth G E de VriesDepartments of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. e.g.e.de.vries@umcg.nl.ORCID http://orcid.org/0000-0002-8949-7425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known regarding tumour target saturation by the programmed death-ligand (PD-L1) antibody atezolizumab. Therefore, tumour saturation by the PD-L1 antibody atezolizumab in patients with advanced solid tumours was assessed using

methodsPatients received 10 mg

resultsGeometric mean tumour SUV

conclusionsCompared to earlier reported pre-treatment CLINICALTRIALS: GOV: NCT02453984, NCT02478099.

Identifiers

PMID42722782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.